Search clinical trials for: Ornithine transcarbamylase vector

Total 3922 results

University of Michigan
Arthritis Foundation

Completed

An Intervention of Electrical Stimulation in Osteoarthritis

Osteoarthritis

United States
United States Army Institute of Surgical Research

Completed

Effect of rFVIIa on Peri-operative Blood Loss in Patients Undergoing Major Burn

Burns

United States
Alcon Research

Withdrawn

Clinical Assessment of Visual Function With the Acrysof ReSTOR Multifocal IOL

Visual Outcomes

United States
CanSino Biologics Inc.
Jiangsu Province Centers for Disease Control and Prevention; Beijing Institute...

Completed

Phase I/II Clinical Trial of Recombinant Novel Coronavirus (COVID-19) Vaccine (Adenovirus Type 5 Vector) for Inhalation

COVID-19

China
Lawson Health Research Institute

Not yet recruiting

Bi-level vs. Single Level ESB in VATS

Acute Pain

Canada
Octapharma

Completed

Bleeding Incidence in VWD Patients Undergoing On-Demand Treatment

Von Willebrand Diseases

Lebanon, Croatia, United States, Hungary, Russian Federation, Ukraine, Belarus, Bulgaria
Baxalta now part of Shire

Completed

Prophylaxis Study of Recombinant Factor VIII Manufactured Protein-Free (rAHF-PFM) in Patients With Hemophilia A

Hemophilia A

United States, Poland, Slovenia, Greece, Russian Federation, Hungary, Italy, United Kingdom, Czechia, Austria
Bayer

Completed

Comparison of Efficacy, Safety and Costs of Recombinant FVIII Products Between On-demand and Secondary Prophylaxis Groups in Haemophilia A Patients

Hemophilia

Turkey
Oregon Health and Science University
Baxter Healthcare Corporation

Completed

Prospective Biomarkers of Bone Metabolism in Hemophilia A

Hemophilia | Bone Disease

United States
Octapharma

Completed

Efficacy and Safety Study of Human-cl rhFVIII in PTPs With Severe Hemophilia A

Severe Hemophilia A

Germany, Austria, United Kingdom, Bulgaria
Bayer

Completed

EffeKt Taiwan- Efficacy and Safety of Long-term Treatment With KOGENATE® FS in Taiwan

Hemophilia A

Taiwan
Octagen Corporation
Biomeasure Inc, Ipsen Group

Completed

Study of Recombinant Porcine Factor VIII (FVIII) in Hemophilia and Inhibitors to FVIII

Hemophilia A

United States
Bayer

Active, not recruiting

Drug Use Investigation of Kovaltry in Hemophilia A Patients

Hemophilia A

Japan
Bayer

Completed

BAY81-8973 Pediatric Safety and Efficacy Trial

Haemophilia A

Spain, Russian Federation, United States, Hungary, Italy, Mexico, Norway, Romania, Bulgaria, Canada, Argentina, Denmark, Israel, Poland, Ireland, Latvia, Lithuania
Baxalta now part of Shire

Completed

Study of Pharmacokinetics, Efficacy and Safety of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Hemophilia A Patients - A Continuation of Clinical Study 069901

Hemophilia A

United States, France, Austria, United Kingdom, Germany, Belgium, Canada, Italy, Sweden
Bioverativ Therapeutics Inc.

Completed

Study of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Subjects With Severe Hemophilia A

Severe Hemophilia A

United States, Hong Kong, Israel
Bio Products Laboratory

Completed

A Study to Compare the Pharmacokinetics and Safety of Current Factor VIII Concentrate and Optivate® in Haemophilia A.

Von Willebrand Disease

Poland, United Kingdom
University of Copenhagen
University of Leeds; University of Liverpool

Completed

SATIN The Acute Effect of Orange Nectar With NAXUS Fibre Made by Novel Processing on Satiety and Satiation (SATIN)

Appetite

Denmark
Baxalta now part of Shire

Completed

Pharmacokinetic Study of ADVATE 3000 IU in Previously Treated Patients With Severe Hemophilia A

Hemophilia A

Bulgaria, Russian Federation
Baxalta now part of Shire
Baxter Innovations GmbH

Completed

BAX 855 Dose-Escalation Safety Study

Hemophilia A

Japan, Bulgaria, Germany, United Kingdom
Hoffmann-La Roche
Chugai Pharmaceutical

Completed

A Clinical Trial to Evaluate Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants Without Inhibitors (HAVEN 3)

Hemophilia A

Australia, Taiwan, Korea, Republic of, France, Germany, Italy, South Africa, Spain, United States, Japan, Ireland, Poland, United Kingdom, Costa Rica
Baxalta now part of Shire

Completed

Study of Pharmacokinetics, Efficacy, and Safety of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Pediatric Patients With Hemophilia A

Hemophilia A

United States, Canada, Puerto Rico
Bayer

Completed

Extension at 10 Years of the: "Observational Study Evaluating Efficacy and Costs of Secondary Prophylaxis vs On-demand Therapy With Kogenate Bayer in Patients With Severe Haemophilia A." (POTTER 10)

Hemophilia A

Italy
Bayer

Completed

Non-interventional Observation of Practical Implementation, Efficacy and Safety of Continuous Infusion With KOGENATE Bayer in Surgery (NO PEACKS)

Hemophilia A

Germany, Spain, Austria, Italy, Slovenia, Greece, Netherlands
Bayer

Completed

Kogenate FS Regulatory Post-Marketing Surveillance (KG0910KR)

Hemophilia A

Korea, Republic of
Bayer

Completed

A Post Approval Commitment Study to Gain More Information on How Safe and Effective KOVALTRY is in Chinese Children, Adolescents /Adults With Severe Hemophilia A

Hemophilia A

China
Baxalta now part of Shire

Completed

ADVATE 2 mL Post-Authorization Safety Surveillance (PASS)

Hemophilia A | Congenital Factor VIII (FVIII) Deficiency

United Kingdom, France, Germany, Hungary
Bioverativ Therapeutics Inc.
Swedish Orphan Biovitrum

Completed

Pharmacokinetics and Safety of rFVIIIFc Manufactured at 15,000 L (15K) Scale (Elevate)

Severe Hemophilia A

United States, Australia, New Zealand
University Hospital Ostrava

Completed

Bioelectrical Impedance in Monitoring Hyperhydration and Polyneuromyopathy in Critically Ill Patients

Septic Shock | Respiratory Insufficiency | Hypoxemia | Chronic Obstructive Pulmonary Disease Exacerbation | Lung Ventilator | Hyperhydration | Respiratory Distress Syndrome, Acute

Czechia
University of Pennsylvania

Completed

Redirected MazF-CD4 Autologous T Cells for HIV Gene Therapy (MazF)

HIV

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

EGEN-001 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Recurrent Ovarian Carcinoma | Fallopian Tube Carcinoma | Primary Peritoneal Carcinoma

United States
University of California, San Francisco
London School of Hygiene and Tropical Medicine; University of Southampton; University... and other collaborators

Completed

Evaluation of Reactive Focal Mass Drug Administration (rfMDA) +/- Reactive Focal Vector Control (RAVC) in Namibia

Malaria

Namibia
Fundacio Salut i Envelliment UAB
Mutuam

Completed

Efficacy Study of a Ginger and Cardamom Gelatin for Xerostomy in Terminally Ill Patients

Mouth Diseases | Xerostomia | Salivary Gland Diseases

Spain
University of Virginia

Not yet recruiting

Recombinant vWF Concentrate and ECMO

Bleeding Disorder

United States
National Taiwan University Hospital

Recruiting

ESP vs STB for Pain and Diagraphragm Function for Shoulder Surgery

Rotator Cuff Injuries

Taiwan
Johns Hopkins Bloomberg School of Public Health
National Institute of Mental Health (NIMH)

Completed

A Pilot Peer Mentor Intervention That Trains Black Men Who Have Sex With Men (BMSM) to Use and Promote Uptake of HIV/STI Self-Testing to Peers and Sex Partners: STAR Study (Self-Testing at Your Residence) (STAR)

Sexually Transmitted Diseases | HIV/AIDS

United States
Spine Centre of Southern Denmark
CeraPedics, Inc; Ortotech

Completed

The Clinical Effect of i-FACTOR® Versus Allograft in Non-instrumented Posterolateral Fusion The IVANOS-study (IVANOS)

Low Back Pain | Spinal Stenosis

Denmark
Alcon Research

Completed

Clinical Assessment of Visual Function With the Acrysof ReSTOR Multifocal IOL

Visual Acuity

United States
Novo Nordisk A/S

Completed

Use of rFXIII in Treatment of Congenital FXIII Deficiency, a Prospective Multi-centre Observational Study (mentor™6)

Congenital Bleeding Disorder | Congenital FXIII Deficiency

Spain, United States, Canada, Italy, United Kingdom, Hungary
Klein Buendel, Inc.
Pacific Institute for Research and Evaluation

Completed

Intervening to Prevent Youth Access to Marijuana Phase II

Cannabis

United States
Christopher O'Brien, MD
BioIncept LLC

Withdrawn

Phase II AutoImmune Hepatitis

Hepatitis, Autoimmune
Dr. Benedict Glover
University of Toronto; Abbott

Unknown

Lifestyle Modification for the Treatment of Symptomatic Atrial Fibrillation (LIFE-AF) (LIFE-AF)

Atrial Fibrillation

Canada
University of Toronto

Completed

Cardiovascular Health And Risk Modification in Family Health Teams (Multi-CHARM)

Hypertension | Diabetes | Hyperlipidemia | Cardiovascular Risk Factors

Canada
Washington University School of Medicine
Allergan

Completed

3D Breast Imaging for Cosmetic and Reconstructive Breast Surgery

Hypomastia | Primary Breast Augmentation

United States
Novo Nordisk A/S

Completed

Safety and Efficacy of Monthly Replacement Therapy With Recombinant Factor XIII (rFXIII) in Paediatric Subjects With Congenital Factor XIII A-subunit Deficiency (mentor™5)

Congenital Bleeding Disorder | Congenital FXIII Deficiency

United Kingdom, Israel, United States
Hadassah Medical Organization
BioIncept LLC

Unknown

Safety Study of Preimplantation Factor (PIF-1) to Treat Acute Steroid-Resistant Graft-Versus-Host Disease (GVHD) (PIF1GVHD)

Graft Vs Host Disease

Israel
Bio Products Laboratory

Completed

A Study Investigating Treatment Factor X in People With Factor X Deficiency

Factor X Deficiency

United States, Turkey, Germany, Spain, United Kingdom
Alcon Research

Completed

A Comparison of Visual Function After Bilateral Implantation of Presbyopia-correcting Intraocular Lenses (IOLs)

Cataract

United States
Alcon Research

Completed

Visual Performance of Bilateral AcrySof ReSTOR Aspheric +4

Cataract

United States
Alcon Research

Completed

Visual Function Evaluation of Bilateral AcrySof ReSTOR Aspheric IOL

Cataracts

United States

Search clinical trials for: Ornithine transcarbamylase vector

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Saint Lucia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations